{"release":"wpf-flagship-weight-management","version":"1.0.0","archived":true,"currentVersion":"1.4.0","updatedRecordUrl":"https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=surmount-5-weight-72w","whatChangedUrl":"https://www.worldpeptidefoundation.org/research/changes","licenseClarification":null,"resultsSha256":"4d6c04b6a80bdeb929e3b9a23214e46aa805359dd916be37817f5e751b5c59a6","license":{"name":"Creative Commons Attribution 4.0 International","identifier":"CC-BY-4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"licenseScope":{"covered":["The stable result identifiers (resultId) and the WPF citation strings","WPF's classification of each study's design (kind)","WPF-written estimand summaries (estimand), the analysis-plan section pointers, and the study-specific limitations (limitations)","The field corrections and their basis notes, and the release changelog","The selection, arrangement and structure of the dataset, and its CSV, BibTeX and JSON renderings","The release metadata and checksum file"],"excluded":["The cited papers and their abstracts, figures and tables (publishers and authors)","ClinicalTrials.gov records, posted results, protocols and statistical analysis plans (linked, not redistributed)","Regulator documents and product labels","Bibliographic identifiers and reported numerical facts as stated by their sources","WPF branding, logos and names","WPF films, transcripts and website copy","WPF repository code"],"unclearAndExcluded":["Fields that closely restate source reports: population, comparator, endpoint, followUp, result, uncertainty, discontinuation, funder and trial names. Ownership of this wording is unresolved, so it is outside the licensed scope until the Owner decides otherwise."]},"suggestedAttribution":"World Peptide Foundation, \"WPF Flagship Weight Management\", version 1.0.0 (2026-11-11), https://www.worldpeptidefoundation.org/releases/wpf-flagship-weight-management/1.0.0/release.json. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Please indicate whether you made changes.","result":{"resultId":"surmount-5-weight-72w","candidateId":"semaglutide:1","kind":"direct_head_to_head","trial":"SURMOUNT-5 (phase 3b, open-label)","agents":"Tirzepatide vs semaglutide","pmid":"40353578","doi":"10.1056/NEJMoa2416394","registryId":"NCT05822830","population":"751 adults with obesity, without type 2 diabetes","comparator":"Maximum tolerated dose: tirzepatide 10 or 15 mg vs semaglutide 1.7 or 2.4 mg, once weekly","endpoint":"Percent change in weight from baseline to week 72","followUp":"72 weeks","result":"-20.2% with tirzepatide vs -13.7% with semaglutide (least-squares means; P<0.001)","uncertainty":"95% CI -21.4 to -19.1 (tirzepatide); -14.9 to -12.6 (semaglutide)","discontinuation":"Not stated in the abstract; see the full text.","funder":"Eli Lilly","registryResultsPosted":true,"registryMasking":"None (open-label)","estimand":"Modified treatment-regimen estimand (the plan's primary): participants included regardless of treatment discontinuation or other anti-obesity medication, except switching to the other study drug. The displayed -20.2% and -13.7% match the registry's ANCOVA result over the full analysis set, which is the method the plan specifies for this estimand (§4.3.1); the publication abstract does not name the estimand, so this is verified by method, not by an explicit label.","analysisPlan":{"title":"SURMOUNT-5 Statistical Analysis Plan v3 (approved 23 Oct 2024), ClinicalTrials.gov NCT05822830","url":"https://cdn.clinicaltrials.gov/large-docs/30/NCT05822830/SAP_001.pdf","sections":"§1.1 Primary estimand; §4.3.1 primary analysis; §4.3.2 efficacy-estimand analysis"},"limitations":["Open-label: participants and investigators knew the assigned drug (registry masking: none).","Compared maximum tolerated doses; the results apply to adults with obesity without type 2 diabetes.","Funded by the manufacturer of tirzepatide."],"citation":"SURMOUNT-5 (phase 3b, open-label). Tirzepatide vs semaglutide. PMID 40353578; DOI 10.1056/NEJMoa2416394; NCT05822830. World Peptide Foundation, Flagship weight-management comparison, result surmount-5-weight-72w. https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w","analysisPlanUrl":"https://cdn.clinicaltrials.gov/large-docs/30/NCT05822830/SAP_001.pdf","analysisPlanSections":"§1.1 Primary estimand; §4.3.1 primary analysis; §4.3.2 efficacy-estimand analysis","registryCheckedOn":"2026-11-11","detailUrl":"https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w"}}